Reviewing Argos Therapeutics (ARGS) and Synlogic (SYBX)

Argos Therapeutics (NASDAQ: ARGS) and Synlogic (NASDAQ:SYBX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.


This table compares Argos Therapeutics and Synlogic’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Argos Therapeutics -13,750.64% N/A -120.95%
Synlogic N/A -50.19% -46.76%

Analyst Ratings

This is a summary of recent ratings and target prices for Argos Therapeutics and Synlogic, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Argos Therapeutics 0 1 0 0 2.00
Synlogic 0 1 3 0 2.75

Argos Therapeutics currently has a consensus price target of $24.00, suggesting a potential upside of 1,677.91%. Synlogic has a consensus price target of $18.75, suggesting a potential upside of 54.70%. Given Argos Therapeutics’ higher possible upside, equities research analysts clearly believe Argos Therapeutics is more favorable than Synlogic.

Institutional and Insider Ownership

50.3% of Synlogic shares are held by institutional investors. 28.2% of Argos Therapeutics shares are held by company insiders. Comparatively, 18.6% of Synlogic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Argos Therapeutics and Synlogic’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Argos Therapeutics $950,000.00 8.72 -$53.02 million ($22.45) -0.06
Synlogic N/A N/A -$26.26 million ($4.68) -2.59

Synlogic has lower revenue, but higher earnings than Argos Therapeutics. Synlogic is trading at a lower price-to-earnings ratio than Argos Therapeutics, indicating that it is currently the more affordable of the two stocks.


Synlogic beats Argos Therapeutics on 7 of the 12 factors compared between the two stocks.

About Argos Therapeutics

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

About Synlogic

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply